An endoscopic scoring system for achalasia: the CARS score
- PMID: 38431105
- DOI: 10.1016/j.gie.2024.02.020
An endoscopic scoring system for achalasia: the CARS score
Abstract
Background and aims: The diagnosis of achalasia is associated with an average delay of 2 years. Endoscopic features may prompt an earlier diagnosis. We aimed to develop and test a novel endoscopic score, CARS, for the prediction of achalasia.
Methods: Part 1: Twenty endoscopic videos were taken from patients undergoing endoscopy for dysphagia or reflux. A survey with videos and endoscopic criteria options was distributed to 6 esophagologists and 6 general gastroenterologists. Inter-rater reliability (IRR) was measured and logistic regression was used to evaluate predictive performance. Three rounds of review were conducted to select the final score of 4 components. Part 2: A retrospective review was conducted for consecutive patients who had comprehensive esophageal testing. Each patient had a CARS endoscopic score calculated based on findings reported at endoscopy.
Results: From a video review and analysis of score components, IRR ranged from 0.23 to 0.57 for score components. The final CARS score was selected based on the following 4 components: Contents, Anatomy, Resistance, and Stasis. In a mixed-effects model, the mean score across raters was higher for achalasia compared with nonachalasia subjects (4.44 vs 0.87; P < .01). In part 2 of the study, achalasia patients had a higher mean CARS score compared with those with no or ineffective motility disorder (mean 4.1 vs 1.3; P < .01).
Conclusions: We developed a CARS score based on reliability performance in a video-based survey and tested the score in a clinical setting. The CARS score performed well in predicting achalasia.
Copyright © 2024 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure The following authors disclosed financial relationships: D. A. Carlson: Consulting for Braintree and Medpace. R. F. Souza: consultant for Ironwood Pharmaceuticals, Castle Biosiences, Phathom Pharmaceuticals, IsoThrive, CDx, and AstraZeneca; research support from Phathom Pharmaceuticals and Sanofi. S. J. Spechler: Consultant for Takeda Pharmaceuticals, Interpace Diagnostics, Ironwood Pharmaceuticals, IsoThrive, Phathom Pharmaceuticals, and Castle Biosciences. J. F. Pandolfino: speaker, consultant, and advisory board member for Ethicon, Endogastric Solutions, Medtronic, and Diversatek; patent for FLIP panometry. V. J. A. Konda: honoraria from Medtronic; consultant for Castle Biosciences, Exact Sciences, Sebela, and Ambu. The other authors disclosed no financial relationships.
MeSH terms
LinkOut - more resources
Full Text Sources